Evotec Reports 30-Percent Rise in Q3 Sales Driven by Strong Tools and Tech Reciepts
Evotec this week reported a 30-percent spike in overall Q3 revenues, driven in part by a 28-percent increase in third-party revenues from its Tools and Technologies division.
Group revenues for the Hamburg, Germany-based company increased 30 percent to €24.6 million ($31.6 million) from €19 million in Q3 2005.
In the Tools and Technologies division, overall revenues jumped approximately 32 percent to €5.4 million from €4.1 million in the year-ago period, while third-party revenues rose 28 percent to €5.1 million.
Evotec said the strong quarter for Tools and Technologies was mainly due to the installation of an ultra-high-throughput screening system at the University of Cincinnati Genome Research Institute, for which Evotec received the order at the beginning of the year.
Evotec also turned a €480,000 profit in the Tools and Tech unit, a 126-percent rise over the €1.9 million net loss incurred by the division in the year-ago period.
In other divisions, the Services unit reported a 23-percent rise in Q3 revenues to €17.6 million from €14.3 million in the same quarter last year; while the Pharmaceuticals division reported sales of €2 million in Q3 compared with €680,000 in Q3 2005.
Xenogen Acquisition Helps Caliper Post 25-Percent Rise in Q3 Revenue
Caliper Life Sciences this week said third-quarter revenues increased 24 percent as R&D spending more than doubled and losses surged 250 percent.
Total receipts for the three months ended Sept. 30 increased to $26.5 million from $21.3 million year over year. Most of that revenue came from product sales, which brought in $18.5 million, while services brought in $6 million and licensing and contracts earned $2 million.
The company said much of the increased revenue can be attributed to sales from Xenogen, which Caliper acquired in August.
Caliper CEO said integration of the new company “is ahead of schedule and we are on track to exceed our cost and revenue synergy goals.”
R&D spending increased to $8.7 million from $4.3 million year over year.
The company said net losses increased to $13.5 million from $3.9 million in the year-ago period. Caliper said the Xenogen acquisition was the “most significant factor” fueling the increased loss.
Caliper said it had around $29.8 million in cash, cash equivalents, and marketable securities as of Sept. 30.
The company said it expects fourth-quarter revenues between $34 million and $38 million, which would be improvements of between 26 percent and 41 percent.
Thermo and Fisher Close Merger; Thermo Fisher Scientific Makes Its Debut
Thermo Electron and Fisher Scientific have wrapped up their $10.6 billion merger, the companies said this week.
The resulting behemoth, Thermo Fisher Scientific, will be based in Waltham, Mass., and will trade on the New York Stock Exchange under the symbol "TMO."
It will have approximately $9 billion in revenues this year and 30,000 employees.
As expected, Thermo's shareholders wound up owning approximately 39 percent of the combined company while Fisher shareholders own approximately 61 percent, Thermo Fisher Scientific said.
The companies disclosed their plans to merge in May.
PerkinElmer to Buy Back as Much as $10M of Its Stock Over Four Years
PerkinElmer this week said that it plans to buy back as much as 10 million shares of its common stock over the next four years.
PerkinElmer’s board authorized the buyback, which will be made over the open market or “through privately negotiated transactions,” the company said.
Two weeks ago, PerkinElmer reported that third-quarter revenues rose 7 percent as profits slid 7 percent.